Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
DNA.WS GINKGO BIOWORKS HOLDINGS INC
0.355+0.029+8.90%
Trading Session
02/02 13:42 ET
High
0.370
Open
0.320
Turnover
65.44K
Low
0.305
Pre Close
0.326
Volume
195.40K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Ginkgo Bioworks Holdings Inc. Price Target Cut to $6.00/Share From $10.50 by Raymond James
Ginkgo Bioworks Holdings Inc. Price Target Cut to $6.00/Share From $10.50 by Raymond James
Ginkgo Bioworks Holdings Inc Price Target Raised to $14.50/Share From $11.50 by Raymond James
Ginkgo Bioworks Holdings Inc Price Target Raised to $14.50/Share From $11.50 by Raymond James
Penny Stocks To Buy In May? 3 To Watch Before Next Week
If you're looking for penny stocks to buy, this market offers incredible opportunities. With how stock market volatility has been this month, a fast hand and a keen eye are crucial. When they say that
Ginkgo Bioworks Holdings Inc Is Maintained at Outperform by Raymond James
Ginkgo Bioworks Holdings Inc Is Maintained at Outperform by Raymond James
Did The Smart Money Play Ginkgo Bioworks Holdings Inc. (DNA) Correctly?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
DNA; SRNG Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors With Losses Exceeding $200K of Class Action
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings Inc. ("Ginkgo" or the "Company") (NYSE:DNA, SRNG))) (f/k/a Soaring Eagle Acquisition Corp.) and certa
Ginkgo Bioworks Holdings Inc. Is Maintained at Outperform by Raymond James
Ginkgo Bioworks Holdings Inc. Is Maintained at Outperform by Raymond James
DNA; SRNG Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors of Class Action and Lead Plaintiff Deadline: January 18, 2022
NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings
BRIEF-Ginkgo Bioworks Launches Cell Development Kit Service For Standardized, Low-Cost Entry To Its Cell Programming Platform
Nov 11 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :* GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORMSource text for Eikon:
BRIEF-Synlogic And Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine For The Treatment Of Homocystinuria
Nov 9 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :* SYNLOGIC AND GINKGO BIOWORKS ANNOUNCE INVESTIGATIONAL SYNTHETIC BIOTIC MEDICINE FOR THE TREATMENT OF HOMOCYSTINURIA* SYNLOGIC- COLLABORATION GE
Company Overview
More
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
CEO： Dr. Jason Kelly
Market： NYSE
Listing Date： 09/17/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet